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Abstract
Background: Circulating tumor cells (CTCs) hold great potential in both clinical application and basic research for
the managements of cancer. However, it remains to be an enormous challenge to obtain efficient detection of
pancreatic CTCs. New detection platforms for the detection of pancreatic CTCs are urgently required.
Methods: In the present study, we applied a newly-developed platform integrated subtraction enrichment and
immunostaining-fluorescence in situ hybridization (SE-iFISH) to analyze clinical significance of pancreatic CTCs.
Immunostaining of CK, CD45, DAPI and FISH with the centromere of chromosome 8 (CEP8) were utilized to identify
CTCs. Cells with features of CK+/CD45-/DAPI+/CEP8 = 2, CK+/CD45-/DAPI+/CEP8 > 2, CK-/CD45-/DAPI+/CEP8 > 2
were defined as pancreatic CTCs. The Kaplan-Meier method and Cox proportional hazards model were used to
analyze the relationship of CTC level and other clinicopathological factors with pancreatic cancer clinical outcomes.
Results: CTC count in pancreatic cancer was higher than healthy individuals (median, 3 vs 0 per 7.5 ml; P < 0.001).
SE-iFISH platform yielded a sensitivity of 88 % and specificity of 90 % in pancreatic cancer at the cutoff value of 2
cells/7.5 ml. Pancreatic cancer patients with lower CTC count (<3/7.5 ml) had substantially better overall survival
(OS) compared with these with higher CTC count (≥3/7.5 ml) (15.2 vs 10.2 months, P = 0.023). Multivariate analysis
indicated that higher CTC count was a strong indicator for worse OS (HR = 4.547, P = 0.016).
Conclusion: Our current data showed that CTCs could be detected in pancreatic cancer patients in various stages,
whether localized, locally advanced and metastatic. Besides, CTCs have shown the potential implication in
predicting prognosis of pancreatic cancer.
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Background
Pancreatic cancer is considered as the one of the most
lethal tumor, ranking from eighth and ninth in 2008 in
male and female, respectively, to both seventh in 2012
among cancer-related deaths worldwide [1, 2]. In devel-
oped countries, pancreatic cancer poses a more severe
threat to public health, ranking fifth in man and fourth
in women among cancer-related death [2]. In China,
pancreatic cancer has been included in the ten most
common cancers for male and temporal trend analyses
show the incidence rate increased from 2000 to 2011
[3]. Pancreatic ductal adenocarcinoma (PDAC) is the
most common and malignant subtype, constituting more
than 85 % of all pancreatic malignancy and pancreatic
cancer is referred to PDAC in this study [4]. Pancreatic
cancer has a dismal 5-year survival rate of approximately
6 % and surgery is the only potentially curative therapy,
however, only about 20 % of pancreatic cancers are eli-
gible for resection [5, 6]. The life quality of pancreatic
cancer patients is quite poor, which accelerates the
cancer-related death [7]. Therefore, early detection and
dynamic monitoring of disease progression are crucial
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for better clinical outcome of pancreatic cancers [6].
Conventional imaging examinations such as contrast
enhanced computed tomography (CT) or magnetic res-
onance imaging (MRI) often fails to detect small primary
tumors and small metastasis, optimal treatment oppor-
tunities are usually missed [8]. Although carbohydrate
antigen 19-9 (CA19-9) is widely used in clinical practice,
it is insensitive for early invasive pancreatic cancer and
hard to discriminate some pancreatic cancers from be-
nign diseases [6]. Therefore, there is an urgent need for
novel biomarkers for early diagnose, dynamical monitor-
ing and risk stratification.
Circulating tumor cells (CTCs) are rare tumor cells
disseminated from primary tumors and secondary de-
posits and act as the seeds of distant metastasis. The
concentrations of CTCs in most cancer patients range
from 0 to 10 per 10 mL of peripheral blood [9]. In order
to improve the efficiency of CTC detection, CTC assays
generally include enrichment steps and followed identifi-
cation procedures [10]. Both physical and biological prop-
erties are exploited in the enrichment process. Protein-
based strategies and mRNA-based strategies are frequently
used in the identification process [11]. CellSearch system is
the most intensively tested assay which performs initial
enrichment relying on EpCAM (epithelial cellular adhesion
molecule) and subsequent identification by cytokeratin
(CK) staining of cells in blood samples, but the detection
rates are only 20 % and 5-42 % in resectable and advanced
pancreatic cancer patients, respectively [12, 13]. Some novel
devices should be introduced to promote research and ap-
plication on pancreatic CTCs.
Recently, a detection platform integrated EpCAM-
independent subtraction and immunostaining-fluorescence
in situ hybridization (SE-iFISH) has been developed and
may facilitate the improvement of pancreatic CTCs [14].
SE-iFISH enables efficient depletion of white blood cells
(WBCs) by anti-CD45 antibody and non-hemolytic re-
moval of red blood cells, then in situ phenotypic and karyo-
typic identification and characterization of centromere
probe 8 (CEP8),which could be performed regardless of
EpCAM expression and size variations [15]. In this pro-
spective study, SE-iFISH was applied to detect and
characterize CTCs in pancreatic cancers and then explored
whether CTC number was related to clinicopathological
factors and influenced clinical outcomes.
Methods
Patients and sample collection
This single-center prospective study was performed in
Shanghai Jiao Tong University Affiliated Sixth People’s
Hospital. Twenty-five patients with confirmed ductal
adenocarcinoma of pancreas (including 5 stage I, 8 stage
II, 6 stage III and 6 stage IV) and twenty healthy donors
were enrolled from September, 2013 to September, 2015.
Written informed consents were obtained from all sub-
jects. Histological examination or radiological imaging
analyzed by a multidisciplinary team provided evidence
for the diagnosis of PDAC. All patients were subjected
to first-line gemcitabine based chemotherapy. Clinical
data were collected for age, gender, site of primary
tumor, site and number of metastases, tumor size, lymph
node metastasis, CA19-9 level and clinical outcomes.
TNM staging of pancreatic cancer patients were per-
formed according to American Joint Committee on
Cancer (AJCC) 2010 staging.
Peripheral venous blood (7.5 ml) from each subject
were collected in customized Acid Citrate Dextrose
(ACD)-anticoagulant tubes (Becton Dickinson, NJ, USA)
1 to 10 days before operation and would be processed
within 48 h after collection [16]. Consent forms notify-
ing blood samples to be only applied in the present
study were signed by all subjects. The study was ap-
proved by the Ethics Committee of Shanghai Jiao Tong
University Affiliated Sixth People’s Hospital and was per-
formed according to the Declaration of Helsinki
Principles.
Subtraction enrichment
The process for detection of pancreatic CTCs was simi-
lar to previous studies [15, 17]. In brief, 7.5 ml periph-
eral venous blood was centrifuged at 800 g for 8 min at
room temperature, then, supernatants above the red
blood cells were removed to deplete serum. The left
components were mixed with 3 ml hCTC Separation
Matrix. The solution was centrifuged at 450 g for 8 min
and white buffy was removed to another centrifuge tube,
thus depleting red blood cells. The removed white buffy
was incubated with 150 μL immunomagnetic particles
conjugated to anti-CD45 monoclonal antibody for
10 min and then they were subjected to magnetic separ-
ation. Bead-free solution were then transferred to centri-
fuge tube and washed twice. The resulting cell pellet was
mixed with fixative and applied onto coated CTC slides.
The slides underwent drying process at 32 °C for 4 h
were suitable for iFISH.
Immunofluorescent staining of CTCs
The identification of CTCs was performed according to kit
instruction (Cytelligen). The slides were socked in 2 × SSC
at 27 °C for 10 min and dehydrated in 100 % ethanol for
2 min. Centromere Probe 8 (CEP8) SpectrumOrange
(Vysis, Abbott Laboratories, Abbott Park, IL, USA) were
denatured at 76 °C for 5 min hybridized at 37 °C for
90 min, and the cells were incubated with 200 μl Antibody
Preparation Solution-1, 1 μl monoclonal anti-CK18 conju-
gated to Alexa Fluor 488 and 1 μl monoclonal anti-CD45
conjugated to Alexa Fluor 594 (Cytelligen). The slides were
incubated at 30 °C for 2 h in the dark. Finally, sample was
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washed twice, followed by mounting with 4′,6-diamidino-
2-phenylindole (DAPI, Vector laboratories, CA, USA)
containing mounting media and subsequently subjected to
fluorescence microscope.
Measurement of CA19-9
Peripheral venous blood (3 ml) was collected into non-
anticoagulant blood-collecting tubes (Becton Dickinson,
Franklin Lakes, NJ, USA) via centrifugation (1,500 g) at
room temperature for 10 min, CA19-9 was measured
from the supernatant by using an automatic immunoassay
analyzer Cobas e601 (Roche, Pleasanton, CA, USA). The
reference range of CA19-9 was less than 37 U/ml.
Statistical analysis
Statistical analysis was performed with SPSS 17.0 soft-
ware for windows where a P value less than 0.05 was
considered statistically significant. The subject’s receiver
operating characteristics (ROC) curve was plotted to
analyze the sensitivity and specificity of CTCs. Graphpad
Prism was used to produce Kaplan-Meier survival
curves and log-rank test was used to compare the
difference of overall survival (OS). Univariate and
multivariate Cox proportional hazards regression ana-
lysis were carried out to identify independent risk
factor for clinical outcomes [18]. All the statistical
tests were two-sided.
Results
Identification of CTCs from pancreatic cancer patients
Various kinds of cells were differentiated by epithelial
marker (CK), hematopoietic WBC marker (CD45), exist-
ence of cell nucleus (DAPI) and chromosome ploidy
(CEP8). These biomarkers had been frequently applied
in previous studies in some cancer types [17, 19]. There-
fore, we were inspired by previous studies and adopted
these markers to identify CTCs in pancreatic cancers. In
general, CTCs were characterized as nucleated cells with
epithelial markers and/or hyperdiploid but without CD45
(Fig. 1). To be specific, CTCs were defined as CK+/CD45-/
DAPI+/CEP8 = 2, CK+/CD45-/DAPI+/CEP8 > 2, CK-/CD4
5-/DAPI+/CEP8 > 2. CK-/CD45+/DAPI+/CEP8 = 2 was
defined as WBC and CK-/CD45-/DAPI+/CEP8 = 2 were
defined as indeterminate cells.
According to the above definition, a total of 103
CTCs were detected among the 25 pancreatic cancer
patients. The features of most CTCs were CK-/
CD45-/DAPI+/CEP8 > 2, which appeared in 24 of the
25 pancreatic cancer patients and accounted for
96.1 % of the whole CTCs. Only 1 was CK+/CD45-/
DAPI+/CEP8 = 2 in 1 pancreatic cancer patient and 3
were CK+/CD45-/DAPI+/CEP8 > 2 in 2 pancreatic
cancer patients. In addition, 6 CTCs in 4 healthy con-
trols were CK-/CD45-/DAPI+/CEP8 > 2 and positive
CK was not detected among them. The indeterminate
cells were quite common. Among pancreatic cancer
Fig. 1 Identification of CTCs in pancreatic cancer by SE-iFISH platform. CK: green, CEP8: orange, DAPI: blue, CD45: red. a CK+/CD45-/DAPI+/CEP8 =
2 (white arrow); b CK+/CD45-/DAPI+/CEP8 > 2 (white arrow); c CK-/CD45+/DAPI+/CEP8 > 2 (white arrow); d CK-/CD45+/DAPI+/CEP8 = 2 (red arrow),
CK-/CD45-/DAPI+/CEP8 = 2 (green arrow)
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patients, indeterminate cells appeared in 21 of the 25
subjects with a median number of 4 CTCs/7.5 ml
(range, 0-8 CTCs/7.5 ml). Among healthy controls,
indeterminate cells appeared in 13 of the 20 subjects
with a median number of 1 CTCs/7.5 ml (range, 0-5
CTCs/7.5 ml).
CTCs in pancreatic cancer patients and healthy controls
According to above definition, CTC number was 0-13
CTCs/7.5 ml (median number, 3 CTCs/7.5 ml) in
pancreatic cancer patients and 0-2 CTCs/7.5 ml (me-
dian number, 0 CTCs/7.5 ml) in health donors. These
difference were statistically significant (P < 0.001)
(Fig. 2a). CA19-9 and TNM stage were both import-
ant clinico-pathological factors for pancreatic cancer,
therefore we compared the relationship between these
two factors and CTC enumeration. The median CTC
number per 7.5 ml peripheral blood in stage I-II and
stage III-IV were 3 (range, 0-7) and 3.5 (range, 2-13),
respectively, no significant difference were found
between them (P = 0.263) (Fig. 2b). The median
CA19-9 level was 216 U/ml (range, 0.6-6540 U/ml)
and CA19-9 levels were elevated (>37 U/ml) in 20 of
the 25 pancreatic cancer patients (80 %). The Spear-
man correlation (R) between CA19-9 levels and CTC
levels was 0.005 (P = 0.982), so CA19-9 and CTC
were relatively independent parameters (Fig. 2c).
Furthermore, CTC enumeration was not associated
with gender, age, tumor size, lymph node metastasis,
and distant metastasis.
In order to discriminate pancreatic cancer patients
from healthy controls, receiver operating characteristic
(ROC) curve was plotted to determine sensitivity and
specificity of CTCs measured by SE-iFISH platform
(Fig. 2d). According to Yourdon’s index, cutoff values
of 1 CTC/7.5 ml, 2 CTCs/7.5 ml, 3 CTCs/7.5 ml, and
5 CTCs/7.5 ml yielded sensitivities of 96 %, 88 %, 68
%, 32 % and specificities of 80 %, 90 %, 100 %, 100 %.
Therefore, we defined cutoff as 2 CTCs/7.5 ml (AUC =
0.954) and a CTC-positive patient was defined as one
whose CTC count in 7.5 mL peripheral venous blood
was ≥2. The positive rate of CTCs in stage I–II and
stage III-IV were 92.3 % (12/13) and 83.3 % (10/12),
with no significant difference between them (P =
0.593). Similarly, CTC-positive rates among patients
with lower CA19-9 level (<200 U/ml) were not sig-
nificantly different with these with higher CA19-9
level (≥200 U/ml) (P = 1.000). Noticeably, 5 patients
with normal CA19-9 levels were all CTC-positive pa-
tients, so the detection rate of pancreatic cancer
could reach 100 % when CTC detection and CA19-9
detection were combined. In addition, CTC positive
rates were not significantly associated with gender,
age, tumor size, lymph node metastasis, and distant
metastasis (Table 1).
Fig. 2 CTC count in pancreatic cancer patients and healthy controls. a, Distribution of CTCs in diagnosed pancreatic cancer and health controls,
existence of CTCs in 25 pancreatic cancer patients and 20 healthy controls were examined. b Distribution of CTCs in patients with pancreatic
cancer according to pathological staging (TNM). c Comparison of circulating tumor cells and CA19-9 as blood-based markers. The blue horizontal
dashed line indicated the CA 19-9 threshold of 37 U/ml. d ROC curves for CTCs count to discriminate pancreatic cancer patients from healthy
controls. The cutoff value was defined as 2 CTCs/7.5 ml
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Survival analysis
During the diligent follow-up of 24 months, the median
follow-up time was 10.2 months (range, 3.9-21.1 months)
for deceased patients and 10.3 months (range, 7.5–
11.3 months) for living patients. The median OS of the
25 pancreatic cancer patients was 10.2 months (range,
3.9-21.6 months). Patients in stage I-II had a signifi-
cantly longer median OS compared to these in stage
III-IV (13.4 vs 7.5 months, P = 0.001). To evaluate the
influence of the cutoff of CTC count and CA9-9 level
on the hazard ratios of OS, the CTC number of 2, 3, 5
per 7.5 ml and CA19-9 value of 37, 200, 1000 per ml
were tested for correlation with OS by Kaplan-Meier
method. Finally, 3 CTCs/7.5 ml and 200 U/ml were chosen
to analyze the prognostic significance of CA19-9 and CTCs,
respectively. The median OS in patients with CTC < 3/
7.5 ml was significantly superior to these with CTC ≥ 3/
7.5 ml (15.2 vs 10.2 months, P = 0.023) (Fig. 3a). Similarly,
the OS was favorable in patients with a level of CA19-9 <
200 U/ml compared to these with a value above (14.5 vs
8.4 months, P = 0.007) (Fig. 3b). We also strived to explore
the correlation between OS and multiploidy of chromo-
some 8 (containing pentaploidy and those > 5 copies), but
failed to find the prognostic significance (P = 0.119).
CTC enumeration and other clinical factors, including
sex, age, TNM staging, and CA19-9 level were subjected
univariate Cox proportional hazards regression analysis
to determine if they were correlated to OS. Only the
clinical factors that were significantly associated with OS
by the univariate analysis were included in the multivari-
ate Cox regression analyses (Table 2). As a result, CTC
count, TNM staging, CA19-9 level, and age were quali-
fied for further analysis. In the multivariate Cox propor-
tional hazards regression analysis, CTC count remained
to be a strong predictor of OS (HR, 4.547; 95 % CI:
1.323–15.625; P = 0.016).
Discussion
Circulating tumor cells have attracted more and more
attention in both cancer research and clinical practice as
a useful surrogate biomarker. It has been reported that
CTCs could be detected in all stages of pancreatic
cancer and even pre-cancerous disease [20–22], there-
fore, CTCs could be regarded as the source of metasta-
sis. Because most imaging modalities failed to detected
pancreatic lesions smaller than 1 cm, CTCs are promis-
ing to detect the occult primary or metastatic tumors
[23]. CTCs could predict an unfavorable prognosis,
which may influence the treatment decision for better
management of pancreatic cancer in clinic [12, 13].
What’s more, CTCs cultured in vivo and vitro have
potential implications for drug sensitivity screening,
metastatic mechanism and drug resistance, which will
promote further study on pancreatic cancer [24, 25].
In this study, SE-iFISH was applied to detect CTCs in
pancreatic cancer of various stages. This distinguished
subtraction enrichment took advantage of anti-WBC
markers antibodies to ensure the depletion of WBCs (as
high as 99.99 %) and minimum hypotonic injury to
CTCs [14, 26]. Conventional EpCAM-dependent enrich-
ment methods have some inherent limitations which
hindered the efficient detection of pancreatic CTCs. One
the one hand, EpCAM was expressed only in about 20 %
of pancreatic patients through immunomagnetic
Fig. 3 OS in patients different level of CTCs and CA19-9. a OS in patients
with lower CTC count (CTC < 3/7.5 ml ) had better OS compared these
with higher CTC count (CTC≥ 3/7.5 ml) (15.2 vs 10.2 months, P= 0.023);
b OS in patients with lower CA19-9 level (CA19-9 < 200 U/ml) was superior
to these with higher CA19-9 level (CA19-9≥ 200 U/ml) (14.5 vs 8.4 months,
P= 0.007)
Table 1 The relationship between CTC-positive rate and clinico-
pathological characteristics
Variations Number (%) No of patients P
CTC-positive CTC-negative
Gender
Male 16 13 3 0.280
Female 9 9 0
Age
<60 8 7 1 1.000
≥60 17 15 2
Tumor stage
I-II 13 12 1 0.593
III-IV 12 10 2
Tumor size
T1-T2 9 8 1 1.000
T3-T4 16 14 2
Lymph nodes
N0 8 8 0 0.527
N1 17 14 3
Metastasis
M0 19 18 1 0.133
M1 6 4 2
CA19-9
<200 U/ml 12 11 1 1.000
≥200 U/ml 13 11 2
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enrichment by using the antibodies targeting mucin 1
and EpCAM [27]. On the other hand, anti-EpCAM anti-
body could trigger intracellular signaling pathways, such
as cell adhesion, proliferation, which had an impact on
the following functional analysis [28, 29]. The modified
enrichment method yields CTCs regardless of the
EpCAM expression status and cell size.
In the identification process, CEP8, CK, CD45 and
DAPI were combined to detect CTCs. Since aneuploidy
is a typical common cytogenetic abnormality malignant
cells, this feature could be exploited for CTC detection
[30]. Previous studies have revealed that centrosome
abnormalities appeared in 85 % of pancreatic cancers
and centrosome abnormalities of chromosome 8 ap-
peared in all of 16 analyzed pancreatic cell lines using
FISH, thus, the variation of chromosome numbers could
be reflected by CEP8 [31, 32]. In our series, almost all
CTCs harbored multiple CEP8 (≥3). Aneuploidy of
chromosome 8 examined by CEP8-FISH also occurred
in other cancer types, such as lung, esophageal, gastric,
colon, bladder, and hepatocellular carcinomas and so on
[15]. The aneuploidy of chromosome could affect the
sensitivity of chemotherapy. Yilin Li et al. reported that
the primary chemoresistance of triploid CTCs was in-
trinsic and chemoresistance for tetraploid and multiploid
CTCs were acquired in gastric cancer, which cast light
on the functional analysis of aneuploidy of chromosome
8 [17]. In addition, CEP8 combined with CEP7 have also
been utilized to identify in lung cancer and increased the
detection rate compared to CEP8 alone or CK-based
method [19, 33]. For these cancer types with low detec-
tion rate with single centrosome probe, multiple probes
are feasible to improve sensitivity.
Cytokeratins are most frequently used epithelial markers
but could be down-regulated and even missed in the epi-
thelial to mesenchymal transition (EMT) process [34–36].
This theory could account for the fact that most CTCs
detected by SE-iFISH were usually CK-negative [15, 37, 38].
Having analyzed the significance of subtraction enrichment,
CEP8 and CK, the definition of CTCs could be further
understood. Cells with characteristics of CK+/CD45-/
DAPI+/CEP8 = 2, CK+/CD45-/DAPI+/CEP8 > 2, CK-/
CD45-/DAPI+/CEP8 > 2 were CTCs because of positive
epithelial and/or hyperdiploid. Cells with characteristics of
CK-/CD45+/DAPI+/CEP8 = 2 were WBCs because CD45
is leukocyte-specific transmembrane protein tyrosine
phosphatase and diploid of chromosome 8 [39, 40]. Cells
with features of CK-/CD45-/DAPI+/CEP8 = 2 were
indeterminate cells, which could be either WBCs with
unstained human anti-CD45 antibody or tumor cells with
negative CK. However, the clinical significance of these
indeterminate cells was still unclear.
In the present study, SE-iFISH achieved a sensitivity of
88 % and specificity of 90 % at the cutoff value of 2 CTCs/
7.5 ml in pancreatic cancer. CTC detection rates were
independent of some conventional clinicopathological
factors, such as TNM staging, CA19-9 level, gender and
sex. However, the relationship between CTC amount and
age, gender, tumor size, CA19-9 may be false negative
since this conclusion was drawn from a small cohort only
including 25 pancreatic cancer cases. So we should pay
attention to this point and make proper explanation on
this conclusion. Specially, CTCs could be detected in
early-stage pancreatic cancer and this may promote the
early diagnose of pancreatic cancer [41]. CTCs are most
useful at the early stage of pancreatic cancer because there
are multiple treatment options to prolong the survival and
the clinical outcomes of late-stage pancreatic cancer are
dismal despite exhausted managements. CA19-9 is the
most commonly used tumor marker in monitoring
response to treatment for pancreatic cancer but was not
recommended as a screening test due to poor and variable
sensitivity (70–90 %) and specificity (68–91 %) [6]. Besides,
about 5 % of population was Lewisa-b- and no elevation in
Table 2 Univariate and multivariate Cox proportional hazards regression analysis for prediction of OS
Parameter P value HR 95 % CI
Univariate Cox proportional hazards regression analysis
CTC≥ 3/7.5 ml 0.037 3.383 1.079–10.608
Higher TNM staging 0.014 4.689 1.374–16.000
CA19-9≥ 200 U/ml <0.001 3.216 1.674–6.192
Age≥ 60 0.040 3.853 1.063–13.967
Multivariate Cox proportional hazards regression analysis
CTC≥ 3/7.5 ml 0.016 4.547 1.323–15.625
Higher TNM staging 0.012 2.742 1.245–6.041
CA19-9≥ 200 U/ml 0.248 2.332 0.555–9.796
Age≥ 60 0.366 1.990 0.447–8.863
Note: Cox proportional hazards models. All statistical tests were two-sided. CTCs were collected in 7.5 ml peripheral venous blood. OS, overall survival; CTC, circulating
tumor cell; HR, hazard ratio; CI, confidence interval
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CA19-9 levels will occurred in them [42]. Combination of
CTC and CA19-9 detection will significantly increase the
detection pancreatic cancer. In this study, the detection rate
of pancreatic cancer reached 100 % by combing CTC and
CA19-9. From the standpoint of diagnose, CTC number
was a complementary parameter of CA19-9 level in diagno-
sis of pancreatic cancer. Therefore, CTCs and CA19-9 may
work as a useful screening tool for individuals with high-
risk for pancreatic cancer [21].
The prognostic significance of CTCs in pancreatic
cancer is still controversial. It seems that the conclusion
was related to diversified detection platform, such as
CellSearch system, size-based CTC and SE-iFISH. Bidard
et al. reported that 9 out of 79 patients (11 %) have one
or more CTCs by CellSearch system, and the difference
in OS was found (RR = 2.5, P = 0.01) but progress free
survival wasn’t found (P = 0.24) between CTC-positive
patients and CTC-negative patients [13]. Due to the
small number and low detection rate, the statistical
power to confirm the conclusion is not enough. Re-
cently, an Italian study team adopting the same method
failed to found significance in both overall and disease-
free survival between CTC-positive and CTC-negative
patients, but they found CTCs appeared in portal vein
predicated liver metastases [12]. The low number of
CTCs detected by CellSearch system may stem from low
or negative expression of EpCAM and/or CKs [43].
Since the EpCAM-dependent device couldn’t produce
satisfactory results, EpCAM-independent device have
been applied to pancreatic CTCs. Size-based devices
were used to detect CTCs more accurately and effi-
ciently. However, different modification of sized-based
device also yielded different conclusions. L Khoja et al.
isolated blood samples via isolation by size of epithelial
tumor cells (ISET) and then identify them solely by mor-
phological characters, such as nuclear to cytoplasmic ra-
tio, diameter, hyperchromatic nuclei and cellular shape
[43]. Although they detected CTCs in 93 % of pancreatic
cancer patients, they didn’t find significant difference in
both progress free survival (P = 0.85) and OS (P = 0.36)
[43]. Birte Kulemann et al. adopted another size-based
device, ScreenCell, to enrich CTCs and then identify
them by morphological features. Similarly, they also
failed to reveal the prognostic significance of CTCs [34].
Recently, a study took advantage of ISET device and
CTCs were defined according to cell size, and expression
of cytokeratin (epithelial marker), vimentin (mesenchy-
mal marker), CD45 [22]. Then, cytokeratin-positive
CTCs proved to be an adverse factor for OS successfully
(P = 0.008). This success contributed the application of
molecular biomarker and further revealed the underlying
factors for prognosis. Our study confirmed that higher
level of CTCs detected by SE-iFISH method was associ-
ated with adverse OS (P = 0.023, HR = 4.547) [37]. CTC
level, together with TNM stage and CA19-9 level could
predict the survival of pancreatic cancer. Pancreatic can-
cer patients with high level of CTCs tend to have worse
prognosis and efficient managements, including accurate
diagnose, optimal surgical scheme and medical treat-
ment should be assigned to improve clinical outcomes.
Although this study was a prospect study, there were
several limitations. Firstly, the sample size was still quite
small and the number of patients in various pathological
stages was low. So, they were roughly divided into two
subgroups to analyze the difference of CTC number and
OS. Still, the difference of OS between patients in stage
I–II and stage III-IV was statistically significant. Sec-
ondly, the dynamic monitoring of CTCs was not per-
formed in this study due to high cost of detection.
Previous studies have reported CTC enumeration
change during perioperative period in a fraction of
patients, however, CTC enumeration after several cycles
of chemotherapy and the significance of CTC change still
required further study [19, 37]. Thirdly, we presented the
AUC in the cross-sectional analysis and the cutoffs of
CTCs and CA19-9 in the prospective analysis. These re-
sults might be applicable for pancreatic cancer patients
with similar characteristics including clinical stages of
cancer. However, the external validity of the results was
unknown. Therefore, more verification experiments are
expected to further confirm the present conclusion and
these future researches will be conductive to promoting
the clinical application of CTC detection.
Conclusions
In summary, SE-iFISH platform could detect CTCs in
pancreatic cancer of various pathological stages. The
sensitivity and specificity were 88 % and 90 % at the cut-
off value of 2 cells/7.5 ml. The detection rate of pancre-
atic cancer could be 100 % when CTC level and CA19-9
level were combined. What’s more, higher level of CTCs
successfully predicted unfavorable prognosis and this
parameter will inform the clinicians to pay special atten-
tion to CTC-positive patients.
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